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Abstract
Late-stage neuropathological hallmarks of Alzheimer’s disease (AD) are b-amyloid (bA) and hyperphosphorylated tau
peptides, aggregated into plaques and tangles, respectively. Corresponding phenotypes have been mimicked in existing
transgenic mice, however, the translational value of aggressive over-expression has recently been questioned. As controlled
gene expression may offer animal models with better predictive validity, we set out to design a transgenic mouse model
that circumvents complications arising from pronuclear injection and massive over-expression, by targeted insertion of
human mutated amyloid and tau transgenes, under the forebrain- and neurone-specific CaMKIIa promoter, termed
PLB1Double. Crossing with an existing presenilin 1 line resulted in PLB1Triple mice. PLB1Triple mice presented with stable gene
expression and age-related pathology of intra-neuronal amyloid and hyperphosphorylated tau in hippocampus and cortex
from 6 months onwards. At this early stage, pre-clinical
18FDG PET/CT imaging revealed cortical hypometabolism with
increased metabolic activity in basal forebrain and ventral midbrain. Quantitative EEG analyses yielded heightened delta
power during wakefulness and REM sleep, and time in wakefulness was already reliably enhanced at 6 months of age. These
anomalies were paralleled by impairments in long-term and short-term hippocampal plasticity and preceded cognitive
deficits in recognition memory, spatial learning, and sleep fragmentation all emerging at ,12 months. These data suggest
that prodromal AD phenotypes can be successfully modelled in transgenic mice devoid of fibrillary plaque or tangle
development. PLB1Triple mice progress from a mild (MCI-like) state to a more comprehensive AD-relevant phenotype, which
are accessible using translational tools such as wireless EEG and microPET/CT.
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Introduction
Genetically modified experimental mouse models have played a
pivotal role in our understanding of Alzheimer’s disease (AD)
aetiology. Although some of these models successfully mimic
disease endophenotypes (e.g. [1]), no mouse model has yet fully
recapitulated human AD pathology, and translational research has
not fulfilled high expectations [2]. The current gold standard
termed 3xTg-AD mouse [3] was generated by pronuclear injection
of two separate transgenes, i.e. human tau (P301L) and APPSWE,
into embryos from presenilin 1 (PS146V) transgenic mice under
the control of neuron-specific Thy1,2 regulatory element. This
approach raises a number of questions since onset of pathology
already occurs in embryonic tissue [4], transgene insertion
artefacts (positional effects) cannot be identified, and the
contribution of individual transgenes to emerging phenotypes
are difficult to resolve. Moreover, genetic stability and thus
reproducibility of data is uncertain [5], and see for example lack of
plaque pathology in follow-up studies [6]. Moreover, early
expression of transgenes in embryonic tissue [4] strongly suggest
developmental and putative compensatory alterations, and heavy
plaque load in young animals mimics late stage AD rather than
mild cognitive impairment (MCI)-like, prodromal stages of the
disease.
Clinical data suggest that a significant proportion of elderly
people without dementia have b-amyloid (bA) deposits, while a
considerable number of AD patients have severely compromised
cognition but few plaques (e.g. [7,8]). Consistently, clearance of
plaques (e.g. by immunisation or secretase inhibition) did not
benefit cognition [9], and it appears that soluble bA species such as
intraneuronal bA oligomers bring about early pathological events
and synaptic dysfunction [10,11].
In animals, neurological as well as cognitive deficits commonly
dissociate from plaque load, and anti-bA immunization of PDAPP
and APP/PS1 mice successfully rescued memory deficits, but
without removal of overall plaque burden [12–14]. Cognitive
deficits thus seem to develop coincidentally prior to extracellular
plaque formation [3]. Physiological and behavioural deficits
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fibrillar plaques [15] supports this contention.
Along the same lines, oligomeric tau species confer higher
toxicity than fibrils and tangles (e.g. [16]) and such granular
oligomers are present in AD patients at Braak stage 0 and intensify
progressively. They can be mimicked in transgenic animal models
and culture preparations (e.g. [17]), confirming the nucleation or
seeding hypothesis as the key process for proteinaceous filament
formation [18]. As early soluble protein species are crucial for both
disease onset and toxicity, their removal would offer greatest
treatment success and future research may benefit from animal
models that mimic such pathologies.
To address this issue, we created an AD model based on single-
copy knock-in of human, mutated APP and Tau. Endophenop-
types were assessed to characterise early AD-like events based on
predominantely intracellular APP/bA and tau expression, with
methods relevant for translational medicine including immuno-
histochemistry, electrophysiology, cognition, actimetry, electro-
encephalography (EEG) and metabolic imaging using microPET.
Results
PLB1Triple mice express mutated human APP and tau
PLB1 mice generated by targeted knock-in of a human APP-
Tau cDNA construct (Fig. 1A) under the control of the mouse
CaMKIIa promoter and crossed with PS1 mice generated a novel
AD mouse line, PLB1Triple (hAPP/hTau/hPS1). Litter size, overall
health and attrition rates were not affected in transgenic
PLB1Triple mice (see Figure S2). Quantitative real-time PCR
(Fig. 1B) confirmed stable forebrain expression (negligible in
cerebellum) of hAPP and htau at both age groups (6 and 12
months) with low inter-subject variability. Hemizygous males and
homozygous females had 2–3 fold higher hAPP and htau mRNA
levels than heterozygous mice, in agreement with random X
chromosome inactivation in females. Therefore, despite the
presence of only one copy, gene load in hemizygous males is
equivalent to homozygous females. subsequent data presented
here are therefore from hemi- and homozygous PLB1Triple mice
based on equal gene dosage.
Immunolabelling of APP/amyloid and tau using human-specific
antibodies (6E10 & DE2B4; Fig. 2) confirmed forebrain expression
ofboth proteinsat,5–6monthsofage,withstainingbeingabsentat
3 months. Staining was preferentially detected intercellularly in
hippocampus and cortex (Fig. 2A&B), and was particularly strong in
somata of principal cells but progressively extended into the neuropil
and dendritic layers (for PLB1WT see Figure S3). Although bAl e v e l s
were below the sensitivity limit of commercially available ELISAs
(tested in tissue form 12 months old mice, data not shown), some
mature bA plaques appeared (see examples in inset, Fig. 2B). Beta-
sheet aggregation was further visualised by Thioflavin-S and Congo
Red staining (Fig. 2C&F) thus confirming mature fibril formation,
though frequently amorphous rather than fibrillary in appearance.
Quantification of plaque load in PLB1Triple mice (based on 6E10
stain) at ,6 months was sparse (,1 plaque per 5 mM coronal brain
section in cortical and hippocampal regions), this increased to 4.2+/
20.5 plaques per section at 21 months (Fig. 2E). Quantification of
aggregated bA (Amorfix A
4 assay, see Methods and Text S1 for
details) also confirmed significantly enhanced levels in 12 and 20+
months old transgenic mice relative to independent C57/BL6 wild-
type mice and PLB1WT (P,0.001). Somewhat unexpectedly, high
numbers of human tau immunoreactive (HT-7, Fig. 3A) and
phospho-tau (AT8, Fig. 3B) neuronal somata emerged already in
PLB1Triple mice from ,6 months onwards throughout cortex and
hippocampus, labelling intensified and extended into the neuropil
with age. These data confirm an age-related, predominantly intra-
neuronal, neuropathology in PLB1Triple mice, and suggest corre-
sponding impairments of physiology in forebrain.
Normal synaptic transmission, but impaired neural
plasticity, in the hippocampus of PLB1Triple mice
Investigations into cellular patho-physiological correlates com-
menced based on field EPSPs recorded in hippocampal slices [19].
Synaptic responses and plasticity in slices from mice aged 3
Figure 1. PLB1 gene construct design and expression levels. A: Genomic sequence of the transgene construct with the CaMKIIa promoter,
human APP (hAPP), an internal ribosome entry site (IRES), followed by Tau (hTau); mutation sites are also indicated. hAPP and hTau were flanked by
loxP and FRT sites, respectively. Neo: Neomycin selection cassette. B: The mRNA expression of hAPP (left) and hTau (right) transgenes determined in
cortex was stable over time; homozygous (homo) animals showed 2–3 fold higher expression levels cf. heterozygous (het) mice. Note that
hemizygous males are listed as homozygous since equal gene load was apparent cf homozygous females due to X chromosome inactivation. Relative
expression levels of hAPP were ,3 fold higher than hTau. Data (mean+SEM) were normalised to GAPDH. *: P,0.05; **: P,0.01.
doi:10.1371/journal.pone.0027068.g001
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(Fig. 4A–C). However, while basic synaptic transmission was also
intact at 6 and 12 months (F,1, P.0.05, Fig. 4A), LTP following
theta-burst stimulation (Fig. 4B) decayed faster in PLB1Triple mice
despite normal post-tetanic potentiation. Robust potentiation of
,140% was recorded in WT mice 60 mins post-tetanus, while the
fEPSP slope in PLB1Triple mice declined steadily to 113% (at 6
month) and 122% (at 12 months), respectively (genotype effect: 6
& 12 months: p,0.05; time x genotype interaction: 6 months:
F(59,2596)=2; P,0.001; 12 months: F(59,2478)=4.5; P,0.001).
Similarly, paired-pulse facilitation (PPF, Fig. 4C), a measure of
pre-synaptic short-term plasticity and transmitter release, was
reduced in both PLB1Triple age groups relative to WT (at 6 months:
40 ms: P,0.05; 100 ms: P,0.01; 200 ms: P,0.001; at 12 months:
40 ms: P,0.05; 100 ms: P,0.01). PPF in slices from age-matched
homozygous PS1 transgenic mice was not affected indicating that
impairments in hippocampal plasticity are endophenotypes related
to hAPP/htau transgene expression. Collectively, age-dependent
impairments in short- and long-term hippocampal plasticity were
uncovered from 6 months of age onwards.
Age-dependent cognitive deficits in PLB1Triple mice
Neuropsychological protocols in PLB1Triple mice determined
phenotypes congruent with the cognitive decline observed in AD
patients. After confirmation of intact sensory-motor abilities (Figure
S4), we explored short-term/working memory in two tasks. In line
with intermediate phenotypes of AD [20], social recognition
memory (expressed as time with an unfamiliar stranger vs. a more
familiar stranger, Fig. 5A) was reduced in 5 months (PLB1WT
P,0.001; PLB1Triple P,0.05) and absent in 12 months old
PLB1Triple (PLB1WT P,0.01; PLB1Triple P.0.05) while sociability
towards one single stranger mouse was unaffected (all P’s for S1
preference ,0.001). This was corroborated in object recognition/
displacementparadigm(Fig.5B),inwhichPLB1Triplemicepresented
with impaired recognition of a novel object at 8 months (PLB1Triple
vs. PLB1WT P,0.05) and amnesia at 12 months (PLB1Triple n.s. vs.
chance level of 50%). After spatial displacement, impairment
occurred only at 12 months (P,0.05) suggesting a delayed onset of
spatial compared to object recognition memory deficits.
In agreement with these results, PLB1Triple mice at 12 months of
age were deficient in spatial acquisition learning as investigated in
the open field water maze (Fig. 5C; genotype effect: F(1,116)=4.5;
P,0.05)), but not at 5 months (F(1,120)=1.7; P.0.05). The
acquisition deficit at 12 months was overcome by further training
(see day 4; Fig. 5C). Consistently higher swim speeds were
observed in PLB1Triple mice in both age groups (P’s,0.05), but
there was no phenotype in thigmotaxis (Figure S5). These data
provide evidence for some deficits in working/short-term recog-
nition memory preceding the emergence of spatial learning
impairments in PLB1Triple mice, and complex deficits in all three
cognitive tasks in the older age-group.
Alterations in brain metabolism in PLB1Triple mice
precede the onset of cognitive deficits
We next investigated whether PLB1Triple mice also present with
changes in brain metabolic activity via in vivo imaging in two age
Figure 2. Amyloid histopathology in homozygous PLB1Triple mice. A–D: Microphotographs from coronal sections of 6, 10, 12–14 months old
animals; scalebars: 50 mm. A–B: Immunoreactivity towards APP/bA (6E10 and DE2B4 antibodies) was progressively seen in somata and processes of
hippocampal pyramidal cells (CA1) and cortical neurones (Ctx). Occasional strong extracellular immunostaining demonstrates the formation of bA
plaques, also visualised by Thioflavin-S and Congo Red fluorescence (C&D), confirming b-sheet protein folding and mature aggregation of
extracellular deposits. Quantification of plaque load was conducted in 21 month old triples (E, 6E10 stain). The bA load was assessed based on the
signal obtained in the Amorfix A
4 assay for aggregated amyloid (see Methods and Text S1) and confirmed significantly enhanced levels in 12 and 20
months old PLB1Triple mice compared with wild-type C57/BL6 and PLB1WT lines (displayed as individual data points, mean and 95% CI, ***:P,0.001).
doi:10.1371/journal.pone.0027068.g002
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18F-DG conducted
under home cage conditions. After data were pooled for genotype
and age, group comparison using voxel-based statistical parametric
mapping (threshold set at P,0.01) generated 2D (Fig. 6A) and 3D
(Fig. 6B) reconstructions of
18F-DG PET/CT images that displayed
regions of significant differences between genotypes, while total
FDG uptake did not differ between groups (data not shown).
Region-specific metabolic activity differed between groups in both
age groups, bilateral hypometabolism (depicted in blue in Fig. 6B)
was already uncovered in PLB1Triple cf. wild-type mice at 5 months
(Fig. 6Ai and Bi), particularly in the occipital and parietal cortices,
while ventral elements, encompassing the basal forebrain, striatum,
thalamus and pons were metabolically hyperactive (Fig. 6Aii, and
red areas in Bi). These phenotypes increased with age (see 6Ai cf.
Aii, and 6Bi cf. Bii), voxel-based quantification of areas affected
confirmed progression with age, i.e. regions with decreased
metabolism expanded from 22.656 mm
3 to 30.336 mm
3 while
hypermatoblism affected 24.448 mm
3 at 5 months vs. 31.104 mm
3
12 months. Though a precise identification of anatomical details is
difficult, structural information obtained from the Digimouse atlas
and alignments with Paxino-Watson coordinates indicated that
hypometabolic cortical regions extended with age to reach the
rostral tip of the prefrontal region as well as the cerebellum in 17
months old PLB1Triple mice (blue areas in Fig. 6B). Furthermore,
areas of hypermetabolism in transgenic mice also expanded, and
stretched from the posterior end of the olfactory bulb, via ventral
orbital cortex, continuing throughout the basal forebrain nuclei,
basal ganglia including caudate and putamen, ventral thalamus and
hypothalamus,ponsandcontinuingintothe brainstem (red areas in
Fig. 6B).
Therefore, PLB1Triple mice displayed a dorso-ventral, bi-
directional change in metabolic activity compared with their
wild-type counterparts. Overall, altered glucose metabolism
emerged as a an early yet progressive, transgene-induced AD-
like trait in this transgenic line, offering a novel translational
approach for future intervention studies.
AD-like sleep disturbances and slowing of EEG in
PLB1Triple mice
Encoding of spatial relationships is subject to hippocampal
processing during post-training sleep and wakefulness. These
parameters are affected in AD patients and assumed to be
mechanistically linked with the emerging memory deficits. As we
have also observed respective changes in a conventional AD
mouse models (e.g. [21]), we here explored alterations in the
activity profile and sleep patterns of PLB1Triple mice as key
features of disease onset and progression (Fig. 7). Actimetry
recorded in home-cage environments (Fig. 7A) confirmed intact
circadian rhythms in both genotypes with heightened ambulatory
activity during the dark periods, typical for nocturnal species.
Relatively high activity in 5 months old PLB1WT mice declined to
lower levels at 12 m (F(1,408)=88; P,0.001), reflecting a natural
ageing trend. By contrast, no age-related decay in motor activity
was noticed in PLB1Triple mice (F,1), due to already low activity
levels at 5 months. As a consequence, PLB1Triple differed from WT
mice in both age groups, with comparatively lower activity at 5
months, and higher activity at 12 months (P,0.01 and 0.001,
respectively).
Quantitative EEG (qEEG) recorded using wireless microchip
technology and EEG/activity-guided vigilance staging (over
24 hrs, in 4 sec bins) yielded significantly enhanced wakefulness
in PLB1Triple mice alongside reduced NREM sleep (Fig. 7B; 5
months: P’s,0.001; 12 months: P’s,0.01). Again, an age-
dependent reduction in NREM sleep together with an increase
in wakefulness was only present in PLB1WT mice (effect of age:
P’s,0.05), but not in PLB1Triples (effect of age: P’s.0.05). Yet,
both genotypes presented with an age-dependent decay in REM
sleep (P’s,0.05), but there was no transgene-specific phenotype.
Latency to first sleep occurrence was also prolonged in PLB1Triple
mice at 12 months (P,0.01) compared with age-matched PLB1WT
mice, but no difference was present at 5 months. Analysis of the
number of NREM events in relation to their length (Fig. 7C)
revealed the occurrence of short bouts of NREM episodes in the
different cohorts. NREM composition was not different at 5
months but short events significantly increased at 12 months in
PLB1Triple mice (genotype effect: F(1,350)=54; P,0.001; geno-
type x bout duration: F(24,350)=3.3; P’s,0.001). It thus appears
that PLB1Triple mice show an early vigilance and activity
phenotype that comprises increased wakefulness amidst reduced
motor activity, which further progresses to yield a delay in sleep
onset and NREM fragmentation at 12 months of age.
Shifts in qEEG spectral power are recognised early indicators
for AD [22,23]. In agreement with this endophenotype, an
increase in delta power was observed in 5 months old PLB1Triple
mice during wakefulness (F(1,90)=7; P,0.01) and NREM
(F(1,90)=2.9; P,0.05) in the prefrontal EEG power spectrum
(Fig. 8); this was paralleled by higher delta power during REM
sleep from parietal recordings (F(1,80)=7; P,0.01). A reduction
in alpha power was consistently uncovered at both recording
positions (F’s.5; P’s,0.05) during wakefulness. Interestingly, a
generalised widening of normalised EEG spectra during NREM
emerged in PLB1Triple mice at 12 months (genotype effect
prefrontal: theta band P,0.01, alpha band P,0.05; parietal:
delta band P,0.01, theta and alpha bands P’s,0.001), confirming
this as a progressive biomarker accompanying sleep fragmenta-
Figure 3. Tau histopathology in PLB1Triple mice. Immunocyto-
chemcial labelling for human tau (HT-7 antibody, A) as well as phospho-
tau (AT-8, B), revealed positive staining in somata and processes in CA1
and cortical neurones from 6 months onwards in PLB1Triple mice.
doi:10.1371/journal.pone.0027068.g003
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appears indicative of early pathology.
Discussion
We here present a phenotypic analysis of a novel transgenic AD
mouse based on targeted knock-in of mutated hAPP and hTau
transgenes. The rational of this approach was a) to avoid positional
effects and mutations of the endogenous mouse genome, a natural
by-product of mice generated via pronuclear injections [5]; b) to
generate a genetically stable AD model based on single copy gene
insertion that can be reliably identified over future generations; c)
employ a neurone- and forebrain-specific regulatory element to
direct transgene expression towards AD-relevant brain structures
and avoid expression in brainstem and cerebellum which may
cause confounding motor phenotypes; and d) to generate a model
that permits the generation of genetically directly comparable
single hAPP and hTau transgenic mice after deletion of either
gene. Not unexpected given the genetic design, PLB1Triple mice
displayed low levels of extracellular protein accumulation and
plaque formation was sparse. Nevertheless, intra-neuronal APP/
bA and tau pathologies were reliably identified and successful
transgene processing confirmed further in a parallel study, where
the same genetic constructs were delivered to different neuronal
preparations by viral transduction [24]. This approach provided
an additional proof of principle for transgene processing and
confirmed mechanisms of neurotoxicity, as secretase and aggre-
gation inhibitors successfully ameliorated toxicity.
In the mouse model described here, expression of single gene
constructs created a patho-physiology reminiscent of early,
prodromal AD consisting of intraneuronal build-up of APP/bA
and tau that appear prior to plaque and tangle deposition. These
constitute early markers of neurotoxicity that lead to synaptic
failure and functional loss [15,25,26]. The emergence of
intraneuronal amyloid correlated with deficits in synaptic plasticity
and cognition in previous studies [3,27], but intracellular bA
oligomeric peptides are not efficiently detected by ELISAs [28,29].
Though more aggressive gene expression and protein build-up
achieved in previous transgenic mice are convenient for
quantification, this approach makes it difficult to dissect early
phenotypes such as subtle [3]cognitive or physiological deteriora-
tion [1,5,30,31]. Detection of bA oligomers in the PLB1Triple mice
required the use of an ultra-sensitive assay specifically designed to
detect low concentrations of aggregated bA. The presence of low
Figure 4. Failure in synaptic plasticity in adult PLB1 mice. Electrophysiological characterisation in the CA1 region of hippocampal slices from
PLB1Triple and PLB1WT mice at 3, 6 and 12 months. A: Input-output relationships of basic synaptic transmission (fEPSP slope vs. stimulus intensity;
mean+SEM) were not affected in PLB1Triple mice. B: LTP time courses (fEPSP slope as % of baseline, +/2 SEM) revealed a significant impairment at 6
and 12 months (genotype effect (P,0.05) and genotype x time interaction (P,0.001)). Arrow: time point of tetanisation. C: Reduced paired-pulse
facilitation was uncovered in PLB1Triple mice at 6 and 12 months, but not in PS1 animals and 3-month old PLB1Triple. Data (mean+SEM) are expressed
as the slope ratio (S2/S1) vs. inter-stimulus interval (ISI). Significances are indicated as *: P,0.05; **: P,0.01; ***: P,0.001.
doi:10.1371/journal.pone.0027068.g004
Phenotypes of PLB1 Mice
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27068but measurable levels of aggregated bA correlate with the
physiological and behavioural deficits which have been charac-
terized in these mice. Low expression of mutated transgenes in
PLB1Triple mice offers the advantage of a prolonged prodromal
phase, leading to moderate cognitive and physiological impair-
ments in rodents at ,12 months. Correspondingly, expression of
Figure 5. Recognition memory and learning in PLB1 mice. A: Social recognition. Time (in seconds) spent with an unfamiliar stranger mouse
(S1) and the corresponding empty compartment (E) at 5 and 1261 months of age. During sociability (left), all groups spent significantly more time in
the vicinity of the unfamiliar mouse compared to the empty holder. During the social memory phase (right), PLB1WT mice discriminated between the
now more familiar first stranger (S1*) and a novel, unfamiliar stranger (S2) in both age groups. PLB1Triple only discriminated between the conspecifics
at 5 months. Data are represented as means+SEM; n.s.: not significant; *: P,0.05; **:P,0.01; ***: P,0.001, arena and representative exploration
patterns are also depicted. B: Object recognition and spatial novelty. Time (in %+SEM) spent with a novel object (left) or relocated object (right)
in PLB1WT and PLB1Triple mice at 8 and 1261 months. PLB1Triple performed worse than PLB1WT in both age groups during object recognition and did
not discriminate between novel and familiar object at 12 months of age. At this age, recognition of spatial novelty was also affected. Significances are
indicated between groups (*), a comparison with chance level is also given ($:P,0.05; $$: P,0.01; $$$: P,0.001). Examples path trajectories are
illustrated on the right. C: Water maze learning. Mean daily path length (+ or 2 SEM) to reach a visible (V) platform, followed by spatial training to
a submerged platform (days 1–4). At 5 and 12 months, PLB1Triple mice were able to locate the visible platform, but were significantly impaired at 12
(but not 5) months in the hidden platform task compared to PLB1WT (P,0.05). Arena set up with representative exploration patterns for day 1–4
(swim path) are depicted.
doi:10.1371/journal.pone.0027068.g005
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pronuclear injection caused exclusively intracellular oligomeric bA
build-up [15]. Despite a lack of extracellular bA aggregates,
hippocampal plasticity and memory declined age-dependently and
phenotypes were similar to the deficits observed here in LTP and
spatial learning in PLB1Triple mice. However, overall impairments
in rodent models expressing intraneuronal bA remain mild [32],
possibly due to the lack of tau pathology. Co-expression of
mutated bA and tau in our PLB1Triple mice progressively affected
synaptic plasticity and ultimately cognition. While its origins in
PLB1Triple remain to be fully resolved, neuronal failure was also
induced in mice with selective expression of the intracellular APP
domain (AICD), without increasing bA itself [33], or in rTg4510
mice expressing soluble tau [34]. Taken together, evidence is now
clearly accumulating for the relevance of early-stage pathologies,
modeled by regulated and specific gene expression, with a focus on
soluble rather than fibrillary histo-pathologies. With regards to the
early tau expression detected here with an unusual pattern
(pronounced HT7 and AT8 stain in nearly all hippocampal and
cortical principle neurons from 6 months onwards), our model
clearly differs from previous lines (e.g. [35]), thus calling for further
analyses of its association with specific cellular compartments and
the role of specific phosphorylation sites.
A second objective of our study was the development of sensitive
translational procedures based on in vivo physiological and imaging
parameters that are coincident with the emergence of intraneural
amyloid/tau and precede a cognitive symptomatic state. Effective
detection of reliable, early translational biomarkers is a major
obstacle not only in research but also in the clinic, where diagnosis
of conversion from MCI toward early dementia is crucial to
identify autonomy impairments in domestic, social, or professional
aspects of life. Deficits in social and facial recognition are typically
absent in MCI and appear on conversion to early AD [36]. We
here report a corresponding phenotype in 12-month old
PLB1Triple mice, which may be related to anomalies in cholinergic
processing [20]. Similarly, working memory, the capacity to
maintain and manipulate information during short time periods, is
often maintained in MCI (see [37] for references) but deteriorates
on conversion to early AD, in agreement with recognition and
spatial memory deficits emerging in older PLB1Triple mice. Early,
but purely experimental, parameters affected comprised hippo-
campal synaptic plasticity, impaired at 6 months when APP/bA
and tau were first detected. Potentially clinically relevant, early
translational biomarkers consisted of metabolic (FDG) changes
that affect dorsal cortices and basal forebrain structures, as well as
EEG spectral power and sleep irregularities, mapping both aging
and transgene-related disease progression [38–40]]. Although the
function of different sleep stages in memory processes is
controversial [41,22], NREM sleep seems critical for the
consolidation of declarative (spatial) memory, and REM for non-
Figure 6. Brain metabolism: FDG PET/CT phenotype of PLB1 mice. In vivo FDG-PET images and surface renderings of PLB1Triple vs. PLB1WT
animals at 5 and 17 months are depicted. Graded 2D coronal sections (A) show the expanding regions of decreased (Ai) or increased metabolism
(Aii) (relative to whole brain activity), the location of the cross sections is indicated on the right. The full extent of metabolic group differences is
illustrated at 5 (Bi) and 17 months (Bii) for lateral (L:left; R:right) and dorsal (P:posterior) views of 3D surface rendered images; areas of significant
metabolic increase (red) and decrease (blue) are based on SPM at P,0.01, the reliability of clusters was also confirmed (family-wise errors, P,0.05). A
surface render of a CT image provides the anatomical reference.
doi:10.1371/journal.pone.0027068.g006
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NREM sleep and fragmentation in PLB1Triple mice may explain
deficits in memory formation in a manner reminiscent of sleep
deprivation, which affects mechanisms required for learning-
induced long-term plasticity, and consistent with an early LTP
phenotype. Again, contributions of bA and tau remain the subject
of future work, but a similar endophenotype may underlie
matching symptoms in patients with early AD [43]. Such a
comprehensive phenotype has not been found in plaque bearing
APP/PS1 mice [44,45], implicating a potential role of intraneu-
ronal tau protein in sleep regulation and circadian function.
The causes and consequences of an overall slowing of EEG
likely reflect failing synchronisation and connectivity between
brain regions [46–49]. Reduced alpha and heightened delta/theta
power during wakefulness and more prominently during REM
sleep are reliable endophenotypes of AD [22,23,39]. It is
conceivable that missing intra- or inter-frequency phase synchrony
would recruit fewer neuronal assemblies for large scale integration
[50,51] and explain working/short-term memory deficits [52]
observed in 12 months old PLB1Triple mice.
A reliable metabolic PET phenotype in AD models has so far
also remained elusive [53,54]. FDG-PET studies conducted in
Tg2576 mice identified areas of hypermetabolism in young-adult
(7-month old) transgenic mice cf. wild-types, but failed to uncover
differences in aged mice [54]. These data suggest that extracellular
amyloid accumulation does not correlate with metabolic changes
in AD relevant brain areas, and both prodromal and early-AD-like
metabolic endophenotypes may be uniquely mimicked in the
PLB1Triple model. Some metabolic (FDG) changes based on
autoradiography have been reported in the 3xTG mouse [55], but
resembled a more global reduction in FDG uptake with little AD-
relevant brain region specificity. The use of in vivo FDG-PET in
Figure 7. Circadian rhythm, wakefulness, and sleep architecture in PLB1WT and PLB1Triple animals at 5 and 12 months of age. A:
Circadian patterns of locomotor activity (mean distance moved 6 SEM, in hourly bins over 24 hrs) were intact in PLB1Triple mice. Only PLB1WT showed
higher activity at 5 months and an age-related reduction (P,0.001). B: Time (in seconds+SEM) spent in vigilance stages wakefulness (WAKE), REM and
NREM sleep, and sleep onset (latency). PLB1Triple animals display increased wakefulness and corresponding reduction in NREM sleep at both ages
(genotype effect: P’s,0.001). REM sleep was affected by age (P,0.01) but not genotype, and onset of sleep delayed in 12 m PLB1Triple mice (P,0.01).
C: A highly significant age-related increase in the number of short-duration NREM events was uncovered in PLB1Triple (right) but not PLB1WT mice
(left). Data represent mean +/2 SEM. *: P,0.05; **:P,0.01; ***: P,0.001.
doi:10.1371/journal.pone.0027068.g007
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and for repeated longitudinal studies. Although amyloid or tau-
specific PET ligands would constitute major progress for research
and diagnosis, experimental work at present still seeks to establish
an agreed procedural gold standard for meaningful comparisons
with clinical imaging. Results from PET studies have to be
interpreted on the basis of the applied registration and
normalisation procedures, and imaging results often reveal
changes in metabolism that are not immediately intuitive [56].
Therefore, the apparent hypermetabolism in subcortical structures
of PLB1Triple mice may reflect changes relative to whole brain
activity consequent to disease progression or age, phenotypes may
occur as a result of inflammation and metabolic activity of glia
[57] or display compensatory neuronal activity. Interestingly,
regions of hypometabolism overlap with areas of transgene
expression and physiological (EEG, LTP) changes. This is an
intriguing finding given the different time-scale of recording
(30 mins for PET, 1 hr of LTP, 24 hours for EEG), but
compatible with the notion that symptoms represent early
phenotypes of a progressively deteriorating neural network.
In summary, the less aggressive but genetically stable nature of
PLB1Triple mice has created a phenotype of prodromal AD/MCI
that has lower levels of APP/bA and tau expression compared to
conventional over-expression models, but allowed us to establish
sensitive translational procedures (microPET/CT imaging and
wireless EEG recording techniques), alongside standard experi-
mental endpoints. Such approaches have the potential to focus
translational research and treatment efforts on early stage AD, the
optimal window for intervention.
Materials and Methods
Transgenic mice
All mice were housed and tested in accordance with European
(FELASA) and UK Home Office regulations, experiments were
approved by the university’s Ethics Board and carried out in
accordance with the Animal (Scientific Procedures) Act 1986 (PPL
60/4085). Mice were kept in a holding room with a 12 hour light/
dark cycle, temperature was maintained at 2362uC and 40–60%
relative humidity. Animals were allowed free access to food
(standard rodent chow) and water. Independent, naive cohorts of
mixed gender were used for a range of in vivo experimental
procedures between 3 and 21 months of age (group details and n’s
as specified below), unless stated otherwise. After in vivo
experimentation, issue was harvested for histological analyses.
PLB1 mice were generated by targeted knock-in of a human
APP-Tau cDNA construct (see Fig. 1A: hAPP: isoform 770
containing Swedish and London mutations; htau: isoform 2N4R
with P301L and R406W mutations) under the control of the
mouse CaMKIIa promoter [58] cloned into the HPRT
TM
targeting vector [59], conducted by genOway, France). To
stabilise expression, an artificial intron derived from a pNN265
vector was fused to the regulatory element and an IRES sequence
inserted between transgenes. Additional LoxP and FRT sites
flanking hAPP and hTau cDNAs, respectively, will enable selective
deletion of either gene in future studies. Gene targeting was
performed in E14Tg2a ES cells subsequently injected into
C57BL6/J blastocysts. APP-Tau expressing animals (PLB1Double)
were crossed with hPS1 (A246E) transgenic mice [60] to generate
PLB1Triple animals (hAPP/hTau/hPS1) and transgenic status
confirmed using PCR and Southern Blot (Figure S1). The Hprt
locus is located on the X chromosome, thus mating of
heterozygous PLB1Triple females with transgenic (hemizygous)
males generated either heterozygous or homozygous females and
hemizygous or WT males. Additional WT controls were derived
from parallel matings between heterozygous PLB1Triple females
with male PLB1WT. For clarity, all animals from PLB1 crossings
that do not carry any transgenes are referred to as PLB1WT.
Genotyping for transgenic cDNA insertion PCR amplification
used forward primer GW496: 59 -ACA ATT GCC TGT GAA
Figure 8. Vigilance-stage specific EEG power spectra in PLB1WT and PLB1Triple animals at 5 and 12 months of age. Normalised power
spectra (delta - alpha bands) from specified vigilance stages are depicted for recording sites above the prefrontal cortex (left) and parietal cortex
(right), significances between genotypes are indicated per frequency band. A shift towards lower frequencies and thus a rise in delta power was
observed at 5 months, while NREM EEGs showed global genotype- and age-related changes at 12 months. *: P,0.05; **:P,0.01; ***: P,0.001.
doi:10.1371/journal.pone.0027068.g008
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59 -TTC GTC CAG ATC ATC CTG ATC GAC AAG AC - 39.
In addition, Hprt wild type (WT) primer pairs 59 -TGT CCT TAG
AAAACA CAT ATC CAG GGT TTA GG -39 and 59 -CTG
GCT TAA AGA CAA CAT CTG GGA GAA AAA -39, enabled
the distinction between hetero- and homozygous animals.
For RNA extraction and quantitative real-time PCR (6 months: n=5
for each genotype; 12 months: n=3 (homozygous PLB1Triples)o r
n=4 (all other groups)) brain samples (4 mm
3) were stored in
‘RNA Later’ solution until extraction with RNeasy Lipid Tissue
Mini Kit (manufacturer’s instructions). Only integrity-controlled
RNA (Agilent 2100 Bioanalyzer, Cheshire, UK, RIN-score .7)
was used for cDNA synthesis with Transcriptor High Fidelity
Reverse transcriptase kit (Roche, Burgess Hill, UK) and gene
expression confirmed with Bio Rad MiniOpticon Real-Time PCR
Detection System using iQ SYBR Green Supermix (BioRad,
Hemel Hempstead, UK) in a final volume of 20 ml. A 100 ng
cDNA equivalent was run (in triplicates) per sample with 3.2 mM
each with transgene (APP and tau) and GAPDH (housekeeping
gene) specific oligomer primers. Quantification was conducted
against standard serial dilutions of plasmids, and copy numbers
normalised vs. GAPDH (Opticon Monitor
TM Software, BioRad,
Hemel Hempstead, UK).
Tissues harvesting and histology (PLB1WT n=3–4, PLB1Triple and
n=4–6 per age group) followed procedures described in [21].
Briefly, brain sections were stained with amyloid antibodies 6E10
(1:200, Cambridge Bioscience) or DE2B4 (1:200, Abcam, Cam-
bridge, UK), HT-7 (1:200, Autogen-Bioclear, Wiltshire, UK) for
human-specific tau and AT-8 (1:25, Autogen-Bioclear) for
phospho-tau. Plaque load in PLB1Triple was quantified by manual
counting based on the 6E10 staining (n=14). Beta-sheet protein
aggregation was further detected using Thioflavin-S (1%, Sigma-
Aldrich) and Congo Red (0.5%, Sigma). Images were taken with a
digital camera (Axocam, Carl Zeiss; Hertfordshire, UK) mounted
on a Zeiss microscope (Axioskop 2 Plus).
For detection of aggregated bA an ultra-sensitive assay was employed
in forebrain samples from 12 months old C57/BL6 WT (n=5), as
well as in transgenic mice (12 months: n=11; 20+months: n=9)
and PLB1WT (n=12) animals (A4 assay, Amorfix, Ontario,
Canada). Briefly, a proprietary sample enrichment protocol was
used to isolate oligomeric bA (see Text S1 for further details).
Following enrichment, samples were eluted and disaggregated to
allow detection of bA [61] based on an immunoassay using
europium-fluorescent beads coupled to the mouse monoclonal
4G10 antibody (N-terminal bA, aa 1–17) and magnetic beads
coupled to the antibodies 1F8 (C-terminal bA, aa 3–40) and 2H12
(C-terminal bA, aa 3–42). The intensity of the europium
fluorescent signal was measured using time resolved fluorescence
(TRF) on each sample in triplicate and was taken as being directly
proportional to the concentration of aggregated bA within the
sample. The limit of detection using this technique is 50 fg of
protein per well.
In vitro hippocampal slice electrophysiology (4–6 animals per each age
group and genotype, number of slices listed below) followed our
previous protocol (e.g. [19] with minor modifications. Briefly,
hippocampi were dissected in ice-cold sucrose aCSF (composition
in mM): 249.2 sucrose, 1.5 KCl, 1.3 MgSO4, 1.5 KH2PO4, 2.89
MgCl2.6H2O, 0.96 CaCl2, 25 NaHCO3 and 10 glucose (pH 7.4,
continuously gassed with 95% O2/5% CO2). Slices (400 mm) were
stored in pre-warmed, oxygenated aCSF (composition in mM:
129.5 NaCl, 1.5 KCl, 1.3 MgSO4, 2.5 CaCl2, 1.5 KH2PO4,2 5
NaHCO3 and 10 glucose; 32uC) for at least 1 h before
experimentation commenced.
Field excitatory postsynaptic potentials (fEPSPs) were recorded
in area CA1, evoked by stimulation of the Schaffer collateral
fibres. Stepwise increases of stimulus intensity until saturation
revealed input/output curves of basic synaptic transmission of
fEPSP slopes (3 months: PLB1WT n=25, PLB1Triple n=24; 6
months: PLB1WT n=16, PLB1Triple n=13, 12 months: PLB1WT
n=26, PLB1Triple n=12).
LTP (3 months: PLB1WT n=8, PLB1Triple n=11; 6 months:
PLB1WT n=23, PLB1Triple n=13, 12 months: PLB1WT n=16,
PLB1Triple n=12) was induced by a theta-burst stimulation (5 Hz,
5 bursts of 4 stimuli (100 Hz), inter-burst interval of 200 msec for
1 second, stimulus intensity: 50% of maximum) and recorded up
to 60 min post-tetanus.
A paired-pulse protocol with inter-stimulus intervals (ISIs,
stimulus intensity: 50% of maximum) of 10, 40, 100 and 200 ms
investigated changes in presynaptic transmitter release and short-
term plasticity (3 months: PLB1WT n=16, PLB1Triple n=11; 6
months: PLB1WT n=10, PLB1Triple n=11, PS1 n=10; 12
months: PLB1WT n=16, PLB1Triple n=11, PS1 n=10).
Social Recognition (5–6 months: PLB1WT n=41; PLB1Triple
n=41; 12–13 months: PLB1WT n=24; PLB1Triple n=24) was
conducted as detailed before in [20]. The apparatus consisted of a
three-chambered box, both side-chambers contained a cylinder for
confinement of a stranger mouse. Test sessions consisted of
habituation, followed by sociability (presentation of one unfamiliar
stranger, S1) and a social memory phase (with a novel, unfamiliar
stranger (S2) and the now familiar stranger (S1*)), 10 min each,
inter-trial interval: 5 mins. Path trajectories in a target area
indexing direct social contacts (4 cm) were video-recorded and
stored online (Ethovision; Noldus IT, Netherlands). Social
interactions were quantified as contact time with S1 cf. the
corresponding empty compartment (sociability), or with S2 cf. S1
(social memory). Animals that showed little exploration (total of
,10 sec in target zone) were excluded (n=2), two animals were
excluded as outliers (.2SD from mean).
Object recognition (8 months: PLB1WT n=15; PLB1Triple n=14;
12 months: PLB1WT n=11; PLB1Triple n=14) followed a protocol
described in [62] with minor modifications. Movement (path
length) in the apparatus (Perspex cylinder, 50 cm diameter; 50 cm
wall height) was tracked (Ethovision Pro 3.1) during 1) Habituation
(2 days, 2 trials, 5 min, ITI: 2 min; trial 1: empty arena; trial 2:
single object) 2) Object novelty: presentation of two identical
objects A (sample phase) followed by one identical (A) and one
novel (B) object (test phase) and 3) Spatial novelty: two novel
objects C and D (sample phase); displacement of one object (test
phase). Object exploration was recorded as % time within the
object perimeter (4 cm). Exclusion criteria: object bias during the
sample phase (n=2); no exploration of objects (n=2); data outliers
(n=2).
Open Field Water maze testing (5–6 months: PLB1WT n=16,
PLB1Triple n=16; 12–13 months: PLB1WT n= 15, PLB1Triple
n=16) was modified from previous protocols [63]. Animals were
allocated target platform locations (Ugo Basile, rising platforms) in
the centre of one quadrant (counterbalanced design) of a circular
water-filled pool (150 cm diameter, 50 cm depth) and pseudo-
randomly released (maximum swim time: 90 s) from 4 cardinal
points (N,E,S,W). They received 4 trials each day for 5 consecutive
days (inter-trial interval 30 min) and swim paths were tracked by
video software (Any-Maze; Ugo Basile) and video-stored (mpeg
files). Day 1: Visible platform pre-training (with curtains). Days 2-
5: Submerged constant platform location, no curtains. The
following parameters were extracted: i) path length to platform;
ii) swim speed; and iii) thigmotaxis (wall hugging). One mouse in
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(.2SD from group mean).
Circadian activity, sleep & electroencephalogram (EEG) assessments
were conducted in a longitudinal design at 5 and 12 months of age
and followed protocols and procedures outlined in detail
previously [21] (PLB1WT n=10, PLB1Triple n=11). Briefly,
circadian rhythms were recorded in PhenoTyper home cages
(Noldus IT, Netherlands) and activity (distance moved) was
sampled (Ethovision, 3.1; Noldus, NL) and averaged into 1 hour
bins over a 24 hr cycle (group means +/2SEM) using in-house
‘Mnimi’ software. After 2 days of habituation, EEG recordings
commenced.
Cranial electrode implants were stereotaxically positioned above
the left and right parietal cortex/dorsal hippocampus (2 mm
posterior to Bregma/1.5 mm lateral to midline), the right medial
prefrontal cortex (2 mm anterior of Bregma, 0.2 mm lateral to
midline), and reference/ground electrodes placed at neutral
locations as described previously. Post surgery recovery lasted
.7 days. EEG was continuously recorded for 24 hrs with a
wireless EEG device (Neurologger, New Behaviour, Switzerland),
that contains a built-in accelerometer (movement) and 4 channels
for recordings (200 Hz sampling, low pass filtered (1–50 Hz)).
Data were downloaded, converted using EEG_Process (Matlab
7, The MathWorks Inc., Natick, USA), and imported into
SleepSign (Kissei Comtec Co. Ltd, Nagano, Japan) for vigilance
staging (wakefulness (wake), REM and NREM sleep) and
extrapolation of power spectra from 4 sec epochs. Fast Fourier
Transform (FFT) was calculated with a resolution of 0.77 Hz,
Hamming window smoothed, and averaged. The spectral bands of
delta (0.5–5 Hz), theta (5–9 Hz), alpha (9–14 Hz), and beta (14–
20 Hz) and gamma (20–50 Hz) were normalised relative to the
absolute maximum power over all frequency bands. Spectral EEG
characteristics of each epoch were pooled for NREM, REM and
wakefulness, based on accelerometer activity and parietal/
hippocampal spectral power (delta and theta power). Time spent
in different vigilance stages was calculated for the 24 hr recording
cycle and distribution of stages analysed (number of events vs.
duration) as an index of fragmentation.
PET Imaging (6 months: PLB1WT n=16; PLB1Triple n=7; 17
months: PLB1WT n=12, PLB1Triple n=13) commenced in
animals fasted overnight and injected intraperitoneally with
18F-
FDG (range: 9.84–17.32 MBq in 0.33–0.5 ml) while conscious.
Uptake (in darkness, 45 mins) occurred on a heating pad (35uC).
For imaging, animals were anesthetized (100 mg/ml VetalarH)/
medetomidine and 1 mg/ml DomitorH) and scanned in supine
position. CT and PET data were collected using a Suinsa ARGUS
dual-ring scanner. The CT was obtained first (at 40 kV and
140 mA beam current) followed by a 40 minute list-mode PET
acquisition (250–700 keV). 3-Dimensional (3D) sinograms were
reduced to 2 dimensions by Fourier rebinning and reconstructed
using two-dimensional ordered subsets expectation maximization
reconstruction algorithms, including corrections for random
coincidence counts, attenuation and photon scatter.
Registration processing to a standard template for voxel-based
analysis were carried out using the Pmod suite (Pmod Technol-
ogies, CH), data were manually aligned with the CT and
registered to the Digimouse atlas [64] inclusive non-linear warping
using the Brain Norm II algorithm.
Voxel (volume: 0.064 mm
3) normalisation was performed cf.
whole brain. Statistical Parametric Mapping (SPM, Functional
Imaging Lab, London, UK) determined genotype and age effects
(at P,0.01 level). Uncorrected SPMs (at p,0.01) produced
clusters of statistically significant voxels which were next subjected
to a second-level statistical analysis (family-wise errors, P,0.05).
Corresponding regions of reliable metabolic increase (red) and
decrease (blue) were mapped onto a CT image for display.
Statistics
Unless indicated otherwise, statistical analyses were performed
with Prism (V.5, GraphPad, USA) using parametric or non-
parametric analysis of variance (one- or two-way as appropriate)
followed by suitable post-tests for selected data pairs. P,0.05 was
considered reliable.
Supporting Information
Figure S1 Genotyping and confirmation of transgene
knock-in. A: PCR of the F1 generation. The genotypes of the
36 pups derived from the F1 breeding were tested by PCR using
primer combinations that detect the targeted Hprt allele. 5 of 36
animals tested were identified as being heterozygous for the Hprt
knock-in. DNA from the targeted ES clone #5B10 was used as a
positive control. PCR without template served as a negative
control. M: 1 kb DNA-Ladder (NEB). B: Southern Blot
analysis of the F1 generation. The genomic DNA of the 2
tested F1 mice (#17763, #17764) were compared with wild-type
DNA (129ES, BL6). The NheI digested DNAs were blotted on
nylon membrane and hybridised with a 59 probe to validate the
zygocity of the Hprt gene mutation in these animals.
(PDF)
Figure S2 Body weight of PLB1Triple and PLB1WT
animals at 5–12 months of age. An overall effect of gender
was observed in both genotypes (***: P,0.001), and a significant
effect of age was noticed in both males (P,0.01) and females
(P,0.05). Data are expressed as means +/2 SEM; n’s at 5,7,9 and
12 months were for females: 34,18,65,32 and males:32,19,56,52,
respectively.
(PDF)
Figure S3 Examples of negative and positive controls
for immunoctychemistry. Sections from PLB1WT (14 months)
and from an APP/PS1 over-expressing mouse (12 months (13)) are
shown for APP antibody DE2B4 and tau antibody HT-7. Scale
bar: 50 mm.
(PDF)
Figure S4 Intact motor performance in PLB1 mice at 10
and 16 months of age. A: Balance Beam: Latency to reach the
end of a 50 cm long beam of different size (square, 5, 11 and
28 mm). Means for all groups are shown (SEM omitted for clarity).
B: Rotarod: Active performance sustained on a rotating rod
(means plus SEM). There was no genotype difference between the
tested cohorts, but an age effect was observed in both paradigms.
*** indicates a highly significant age effect (P,0.01) in both
genotypes.
(PDF)
Figure S5 Thigmotaxis and swim speed during the
water maze task. A: Even though PLB1Triple spent significantly
more time in the thigmotaxis zone on day 1 (visible platform
training, V), there was no overall genotype effect, and PLB1Triple
and PLB1WT mice equally reduced the time spent in the
thigmotaxis zone during spatial learning (overall P.0.05). B:
PLB1Triple mice presented with significantly enhanced velocity
during spatial learning. This was particularly pronounced at 5 m
of age (left, P,0.001) but also observed at 12 m (right, P,0.01).
Accordingly, pathlength and not latency data are presented in the
main manuscript.
(TIF)
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